Search clinical trials for: Erythropoietin stimulating agent

Total 188525 results

Assiut University

Not yet recruiting

Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital

Erythropoietin Resistant Anemia (EPO Resistant Anemia)
Bristol-Myers Squibb

Recruiting

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (ELEMENT-MDS)

Myelodysplastic Syndromes

Canada, United States, China, Australia, France, Greece, Hungary, Germany, Italy, Czechia, Poland, Spain, Brazil, Colombia, India, Mexico, Argentina, Puerto Rico
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine for Poor Graft Function Post Allo-HSCT

Poor Graft Function
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Poor Graft Function
Julia Xu
Carnegie Mellon University; American Society of Hematology

Recruiting

Hydroxyurea and EPO in Sickle Cell Disease (ACHiEvE-SCD)

Sickle Cell Disease | Anemia, Sickle Cell

United States, Nigeria
Hospital Son Espases

Recruiting

Paricalcitol Improves Anemia of Inflammation (PIERAID)

Anemia

Spain
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
University of Louisville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

Anemia of End Stage Renal Disease

United States
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Anaemia | Aspergillosis, Allergic Bronchopulmonary

Australia, Korea, Republic of, Spain, United States, Taiwan, Bulgaria, Mexico, Ukraine, Argentina, Belgium, South Africa, Singapore, Austria, Canada, Netherlands, Russian Federation, Sweden, Turkey, United Kingdom, Germany, Romania and more
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Anemia | Dialysis

Hong Kong, United States, Singapore, Russian Federation
University of Texas Southwestern Medical Center
AMAG Pharmaceuticals, Inc.

Terminated

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery (APART)

Cardiovascular Disease | Anemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Imperial College London

Completed

Predictors of Response to Iron and Erythropoietin Stimulating Agents (PRIME)

Anemia | Renal Failure Chronic
Takeda

Completed

Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease

Anemia | Chronic Kidney Disease | Pure Red Cell Aplasia | Chronic Renal Failure

United Kingdom, France, Germany
Daiichi Sankyo, Inc.
PRA Health Sciences

Completed

Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease

Chronic Renal Disease | Renal Anemia

Czechia, Hungary
GlaxoSmithKline

Completed

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Anaemia

United States, Australia, Korea, Republic of, Canada, Czechia, Norway, Spain, United Kingdom, Russian Federation, Germany, Sweden, Denmark, Poland, France, Hungary, Japan
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease

Anaemia

Japan
Anemia Working Group Romania
Dr Carol Davila Teaching Hospital of Nephrology; Romanian Renal Registry

Withdrawn

Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules (VAES)

Bio-Equivalency of 2 Treatment Schedules in HD Patients

Romania
GlaxoSmithKline
PPD

Completed

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Anaemia

United States, Germany, Canada, Sweden, Denmark, Norway
Hamad Medical Corporation

Completed

Comparison Among Erythropoietin Stimulating Agents

Anemia of End Stage Renal Disease

Qatar
Novartis Pharmaceuticals

Terminated

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (GEPARD)

Myelodysplastic Syndrome (MDS)

Germany
GlaxoSmithKline

Terminated

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

Anemia

United States
Peking University

Unknown

Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

Lymphoma | Anemia | Hematopoietic Stem Cell Transplantation

China
Giovanni FM Strippoli, MD

Completed

The Clinical Evaluation of the Dose of Erythropoietins Trial (CEDOSE)

Kidney Failure, Chronic

Italy
Taipei Veterans General Hospital, Taiwan
Taipei City Hospital

Completed

Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients

Inflammation | Anemia | Malnutrition

Taiwan
Chulalongkorn University
Ministry of Health, Thailand

Unknown

A Prospective, Immunogenicity Surveillance Registry of Erythropoiesis Stimulating Agent (ESA) With Subcutaneous Exposure in Thailand

Erythropoietin
Università degli Studi di Brescia

Completed

Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes Patients With Proliferative Retinopathy (UVA-EVA)

Diabetic Retinopathy

Italy
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis (EMERALD 2)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Bulgaria, Romania, United Kingdom, Italy, Poland, France, Germany, Spain
Affymax
Takeda

Completed

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis (PEARL 2)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Bulgaria, United Kingdom, Czech Republic, Germany, Hungary, Italy, Poland, Puerto Rico, Romania
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis (PEARL 1)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States, Puerto Rico
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis (EMERALD 1)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States
Affymax

Completed

Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United Kingdom, Poland
Affymax

Terminated

Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United Kingdom
Affymax

Completed

Peginesatide for Anemia in Chronic Hemodialysis Patients

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States
Affymax

Completed

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

Cancer | Chemotherapy Induced Anemia

Czech Republic, Poland, United Kingdom
Affymax

Completed

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Cancer | Anemia | Chronic Kidney Disease | Chronic Renal Failure

United Kingdom
Ospedale Regionale di Locarno

Completed

ESAs, Reticulocyte Dynamic and Hemoglobin Variability

Erythropoiesis Stimulating Agent Pharmacodynamics

Switzerland
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Myelodysplastic Syndrome

United States
Affymax

Completed

Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis

Anemia | Chronic Kidney Disease | Chronic Renal Failure

Bulgaria, Romania, United Kingdom
Affymax
Takeda

Completed

Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA

Anemia | Chronic Kidney Disease | Chronic Renal Failure

Russian Federation
Affymax

Terminated

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)

Anemia | Chronic Kidney Disease | Chronic Renal Failure

Bulgaria, Romania, Poland, United Kingdom
Affymax

Terminated

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

Anemia | Chronic Kidney Disease | Chronic Renal Failure

United States
Amgen

Completed

A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex

HIV Infections | Cytopenias

United States
Amgen

Completed

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)

HIV Infections

United States
Cairo University

Not yet recruiting

Effect of Qigong on Sleep Quality in Fibromyalgia

Fibromyalgia

Egypt
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

Pancreatic Ductal Adenocarcinoma
Children's Hospital of Soochow University

Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

AML, Childhood | C-KIT Mutation | Refractory AML | Relapse/Recurrence | Core Binding Factor Acute Myeloid Leukemia

China

Search clinical trials for: Erythropoietin stimulating agent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations